Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT03513029

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
VytronUS, Inc. (from the registry)
Registry
  • NCT NCT03513029
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Czechia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03513029. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-20 (actual); primary completion 2019-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation
Acronym
VITAL
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
VytronUS Ablation System
Lead sponsor
VytronUS, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03513029
Content hash
d7a91fdb6df8f569be0e9f4632e31f8b416b7792165542cb52ec1a9d79c32731